← Leaderboards
Stephen G Rayport
Columbia University Health Sciences
$13,844,103
Attributed
$13,844,103
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,844,103 · 9
By mechanism
R01$10,645,222 · 5
P50$1,139,762 · 1
K02$1,103,285 · 1
R21$955,834 · 2
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Rajesh Narendran$16,481,808
- Gary Struhl$9,934,459
- Isabel Bravo$98,512
- William G Frankle$1,789,715
- Menachem Miodovnik$5,122,859
Others in their field
Top investigators on “Glutamates”
- Merit E Cudkowicz · Massachusetts General Hospital$40,827,833
- Alan G. Barbour · University Of California Irvine$39,660,285
- Scott W Woods · Yale University$33,212,495
- Paul F Worley · Johns Hopkins University$32,678,609
- Richard L Huganir · Johns Hopkins University$30,324,803
- John M Kane · Long Island Jewish Medical Center$28,729,148
Research focus
GlutamatesSynapsesNucleus AccumbensDopamineNeuronsBehavioralGlutaminaseDopaminergic NeuronBaseAffectPsychostimulantTransmission ProcessPhenotypeCorpus Striatum StructureSignal TransductionAttenuatedNeurotransmittersPharmaceutical PreparationsAmphetaminesBrainPharmacotherapyMapsBehaviorGamma-Aminobutyric Acid
Grant awards (42)
Synaptic Actions of Amphetamine in the Striatum$550,811
R01 · FY2025 · DA · contact PI
Synaptic Actions of Amphetamine in the Striatum$548,896
R01 · FY2024 · DA · contact PI
Synaptic Actions of Amphetamine in the Striatum$562,138
R01 · FY2023 · DA · contact PI
Targeting cotransmission for circuit-specific pharmacotherapy$563,259
R01 · FY2022 · MH · contact PI
Targeting cotransmission for circuit-specific pharmacotherapy$563,230
R01 · FY2021 · MH · contact PI
Targeting cotransmission for circuit-specific pharmacotherapy$563,230
R01 · FY2020 · MH · contact PI
Functional connectome analysis of amphetamine action at dopamine neuron synapses$567,165
R01 · FY2019 · DA · contact PI
Targeting cotransmission for circuit-specific pharmacotherapy$563,230
R01 · FY2019 · MH · contact PI
Targeting cotransmission for circuit-specific pharmacotherapy$599,186
R01 · FY2018 · MH · contact PI
Functional connectome analysis of amphetamine action at dopamine neuron synapses$567,165
R01 · FY2018 · DA · contact PI
Functional connectome analysis of amphetamine action at dopamine neuron synapses$600,549
R01 · FY2017 · DA · contact PI
Functional connectome analysis of amphetamine action at dopamine neuron synapses$608,624
R01 · FY2016 · DA · contact PI
Mapping dopamine neuron cotransmission by proximity detection$187,137
R21 · FY2016 · DA · contact PI
Functional connectome analysis of amphetamine action at dopamine neuron synapses$594,220
R01 · FY2015 · DA · contact PI
Mapping dopamine neuron cotransmission by proximity detection$257,197
R21 · FY2015 · DA · contact PI
Therapeutic potential of GLS1 inhibition for the pharmacotherapy of schizophrenia$357,039
R01 · FY2014 · MH · contact PI
Therapeutic potential of GLS1 inhibition for the pharmacotherapy of schizophrenia$342,754
R01 · FY2013 · MH · contact PI
Therapeutic potential of GLS1 inhibition for the pharmacotherapy of schizophrenia$357,010
R01 · FY2012 · MH · contact PI
Therapeutic potential of GLS1 inhibition for the pharmacotherapy of schizophrenia$356,986
R01 · FY2011 · MH · contact PI
Therapeutic potential of GLS1 inhibition for the pharmacotherapy of schizophrenia$369,009
R01 · FY2010 · MH · contact PI
Transgenic analysis of glutamate in sensitization$279,460
R01 · FY2009 · DA · contact PI
Transgenic analysis of glutamate in sensitization$276,734
R01 · FY2008 · DA · contact PI
ETIOLOGIC PATHWAYS TO DOPAMINE DYSFUNCTION$213,699
P50 · FY2008 · MH · contact PI
Psychostimulant sensitization at the synaptic level$122,861
K02 · FY2008 · DA · contact PI
Transgenic analysis of glutamate in sensitization$279,680
R01 · FY2007 · DA · contact PI
ETIOLOGIC PATHWAYS TO DOPAMINE DYSFUNCTION$238,377
P50 · FY2007 · MH · contact PI
Psychostimulant sensitization at the synaptic level$122,861
K02 · FY2007 · DA · contact PI
Transgenic analysis of glutamate in sensitization$285,333
R01 · FY2006 · DA · contact PI
ETIOLOGIC PATHWAYS TO DOPAMINE DYSFUNCTION$234,882
P50 · FY2006 · MH · contact PI
Psychostimulant sensitization at the synaptic level$122,861
K02 · FY2006 · DA · contact PI
Transgenic analysis of glutamate in sensitization$289,514
R01 · FY2005 · DA
ETIOLOGIC PATHWAYS TO DOPAMINE DYSFUNCTION$228,040
P50 · FY2005 · MH
Psychostimulant sensitization at the synaptic level$122,861
K02 · FY2005 · DA
ETIOLOGIC PATHWAYS TO DOPAMINE DYSFUNCTION$224,764
P50 · FY2004 · MH
Psychostimulant sensitization at the synaptic level$122,861
K02 · FY2004 · DA
Glutaminase Knockouts and drug dependence$170,500
R21 · FY2003 · DA
PSYCHOSTIMULANT SENSITIZATION AT THE SYNAPTIC LEVEL$122,245
K02 · FY2003 · DA
Glutaminase Knockouts and drug dependence$170,500
R21 · FY2002 · DA
PSYCHOSTIMULANT SENSITIZATION AT THE SYNAPTIC LEVEL$122,245
K02 · FY2002 · DA
Glutaminase Knockouts and drug dependence$170,500
R21 · FY2001 · DA
PSYCHOSTIMULANT SENSITIZATION AT THE SYNAPTIC LEVEL$122,245
K02 · FY2001 · DA
PSYCHOSTIMULANT SENSITIZATION AT THE SYNAPTIC LEVEL$122,245
K02 · FY2000 · DA